Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine PET Study in Healthy Volunteers and HD
NCT03019289Phase 1Completed
- Sponsor
- Prilenia Therapeutics
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pridopidine in Huntington's disease (HD), sponsored by Prilenia Therapeutics. Primary endpoint: Sigma-1 Receptor Occupancy. Started Apr 2017; status: completed.
02
Drugs
pridopidine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT03019289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019289.